CAS 103775-75-3

Miboplatin

Description:

Miboplatin is a platinum-based chemotherapeutic agent that is primarily investigated for its potential use in cancer treatment. It is a derivative of cisplatin, designed to enhance efficacy and reduce side effects associated with traditional platinum compounds. Miboplatin exhibits characteristics such as a broad spectrum of antitumor activity, particularly against various solid tumors. Its mechanism of action involves the formation of DNA cross-links, which inhibit DNA replication and transcription, ultimately leading to cancer cell death. Miboplatin is noted for its improved solubility and stability compared to other platinum drugs, which may contribute to its therapeutic advantages. Additionally, it has been studied for its ability to overcome resistance mechanisms that often limit the effectiveness of conventional platinum-based therapies. As with many chemotherapeutic agents, the clinical application of Miboplatin is accompanied by potential side effects, including nephrotoxicity and myelosuppression, necessitating careful monitoring during treatment. Ongoing research continues to evaluate its efficacy and safety profile in various cancer types.

Formula: C₁₁H₁₈N₂O₄Pt

InChI: InChI=1S/C6H8O4.C5H12N2.Pt/c7-4(8)6(5(9)10)2-1-3-6;6-4-5-2-1-3-7-5;/h1-3H2,(H,7,8)(H,9,10);5,7H,1-4,6H2;/q;;+2/p-2

InChI key: InChIKey=XXUHLUDUCZQMDI-UHFFFAOYSA-L

SMILES: O=C1[O-][Pt+2]2([NH]3C(C[NH2]2)CCC3)[O-]C(=O)C14CCC4

Synonyms:

• (SP-4-3)-[1,1-Cyclobutanedi(carboxylato-κO)(2-)][(1R,2R)-2-pyrrolidinemethanamine-κN¹,κN²]platinum
• 1,1-Cyclobutanedicarboxylic acid, platinum complex
• 2-Pyrrolidinemethanamine, platinum complex, (R)-
• Dwa 2114R
• Platinum, [1,1-cyclobutanedi(carboxylato-κO)(2-)](2-pyrrolidinemethanamine-κN¹,κN²)-, [SP-4-3-[1R-(cis)]]-
• Platinum, [1,1-cyclobutanedi(carboxylato-κO)(2-)][(1R,2R)-2-pyrrolidinemethanamine-κN¹,κN²]-, (SP-4-3)-
• Platinum, [1,1-cyclobutanedicarboxylato(2-)](2-pyrrolidinemethanamine-N^α,N¹)-, [SP-4-3-(1R-cis)]-
• platinum(2+) cyclobutane-1,1-dicarboxylate - 1-[(2R)-pyrrolidin-2-yl]methanamine (1:1:1)
• Platinum, [1,1-cyclobutanedicarboxylato(2-)](2-pyrrolidinemethanamine-Nα,N1)-, [SP-4-3-(1R-cis)]-
• Platinum, [1,1-cyclobutanedi(carboxylato-κO)(2-)][(1R,2R)-2-pyrrolidinemethanamine-κN1,κN2]-, (SP-4-3)-
• Platinum, [1,1-cyclobutanedi(carboxylato-κO)(2-)](2-pyrrolidinemethanamine-κN1,κN2)-, [SP-4-3-[1R-(cis)]]-
• Miboplatin(Lobaplatin)
• Lobaplatin
• DWA 2114
• Miboplatin

Miboplatin

Controlled Product

CAS: 103775-75-3

Applications Miboplatin is a platinum coordination complexes which have been identified and developed as new antitumor agents in Japan.
References Bioemink, M.J., et al.: J. Biol. Inorg. Chem., 4, 554 (1999); Kudoh, K., et al.: Oncol. Reports., 2, 763 (1995); Kikkawa, F., et al.: Anticancer. Rsch., 13, 891 (1993);

Formula: C₁₁H₁₈N₂O₄Pt

Color and Shape: Neat

Molecular weight: 436.34

Ref: TR-M342100

Miboplatin

CAS: 103775-75-3

Miboplatin is a chemotherapeutic agent that is used to treat cancer and other diseases. It inhibits DNA synthesis by binding to the enzyme topoisomerase II, which maintains the integrity of DNA. Miboplatin has been shown to be cytotoxic at doses of 0.5-2 micrograms/mL in vitro against k562 cells in human serum. It has also been shown to have carcinogenic potential in rats, although not in mice. Miboplatin is given as an oral preparation with sodium carbonate, which reacts with miboplatin to form a solution containing miboplatin and sodium bicarbonate (NaHCO). This solution can be analyzed by various analytical methods, such as thin-layer chromatography (TLC) or gas chromatography (GC). Control analysis is also performed on this solution before administration to the patient. Miboplatin has been studied as a treatment for inflammatory bowel disease and has been found to be

Formula: C₁₁H₁₈N₂O₄Pt

Purity: Min. 95%

Molecular weight: 437.4 g/mol

Ref: 3D-DEA77575

Miboplatin

CAS: 103775-75-3

Formula: C₁₁H₁₈N₂O₄Pt

Molecular weight: 437.36

Ref: ST-EA-CP-C78010